PSP Briefing — Ozempic

Week ending November 8, 2026

1. Self-management questions this week

• Dosing schedule and titration — highest-volume practical theme. Multiple questions asked for the “recommended starting dose,” “how do I increase it,” and “how often should I inject it?” Answers commonly described 0.25 mg once weekly for four weeks, followed by titration. The dosing-specific tally rose to 77, up from 71 last week.
• Missed doses — direct adherence need. Patients asked: “If I miss a dose of Ozempic, what should I do—skip it or take it later?” This generated seven answer variants and is the clearest immediate onboarding/hotline opportunity.
• Administration technique/storage — little or no direct demand detected. No tagged question specifically asked how to perform injection steps, rotate sites, store the pen, or handle a temperature excursion. This should not be interpreted as absence of need; these topics may be underrepresented in the monitored questions.
• Side-effect self-management — limited practical questioning. Questions focused mainly on warnings, interactions, kidney disease, and pancreatitis—not on coping with nausea, vomiting, diarrhea, appetite changes, or when to contact the support team.

2. Where guidance is inconsistent or thin

• Highest-priority inconsistency: missed-dose timing. Responses split between taking the dose if remembered within five days and taking it only when there are at least 48 hours before the next dose. All advised against doubling up, but the different windows could lead to different patient actions. Standardize the patient-facing missed-dose instruction across onboarding, nurse scripts, and digital reminders.
• Practical guidance is often hedged. “Hedging/disclaimer” language appeared 130 times, nearly unchanged from 126 last week. Some answers offer general direction but defer to a prescriber without clearly routing the patient to an actionable support pathway.
• Kidney/GI guidance varies in completeness. Answers generally mention dehydration and monitoring, but not consistently what a patient should do when vomiting, unable to maintain intake, or noticing worsening symptoms. Align symptom-management and escalation talking points with approved materials.

3. Support-pathway visibility

Answers frequently say to contact a prescriber or pharmacist, but do not identify a nurse line, injection educator, or patient support coordinator. Patients are therefore often left to interpret dosing and side-effect guidance independently. Our onboarding and reminder materials should make the human support route explicit.

4. Trend across weeks

Overall volume is steady at 20 questions and 140 responses, matching the prior week. Practical dosing content is increasing (77 vs. 71), while inconsistency flags rose slightly (34 vs. 33). Over the longer trend, inconsistency remains persistently elevated when monitoring volume is high; this is an ongoing standardization issue, not a one-off.

5. Recommended actions

1. Update missed-dose materials immediately to resolve the 48-hour versus five-day conflict; route the final wording for label-aligned review and consider a separate PV/medical-information note because of the practical consequence.
2. Add a prominent nurse-line/support-program callout to onboarding, missed-dose reminders, and side-effect pages.
3. Refresh titration education using one consistent visual schedule and clear “follow your prescribed plan” language.
4. Proactively reinforce injection technique, storage, and GI self-management during enrollment, despite no direct AI volume this week.